Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | Gene editing of NKG2A to enhance NK cell cytotoxicity against multiple myeloma cells

Tobias Bexte • 16 Mar 2022
EBMT 2022
Multiple Myeloma

Tobias Bexte, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, presents the results of a pre-clinical study evaluating the efficacy of CRISPR-based gene editing of the immune checkpoint NKG2A expressed on natural killer (NK) cells against multiple myeloma cells. Overall, NKG2A knockout cells and allogeneic NKG2A knockout cells from healthy donors showed significantly higher tumor cell lysis against different multiple myeloma cell lines and patient-derived primary tumor cells. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Tobias Bexte

3:33
Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells
Tobias Bexte • 25 Apr 2023
0:48
Advantages of primary NK cells for the treatment of patients with hematological malignancies
Tobias Bexte • 16 Mar 2022
0:59
Next steps for gene-edited NK cells in the treatment of hematological malignancies
Tobias Bexte • 16 Mar 2022
2:06
NK CAR-based therapies & future perspectives
Tobias Bexte • 31 Aug 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals